Association Between Pharmacological Treatment of Attention-Deficit/Hyperactivity Disorder and Long-term Unemployment Among Working-Age Individuals in Sweden.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
entrez:
27
4
2022
pubmed:
28
4
2022
medline:
30
4
2022
Statut:
epublish
Résumé
Adults with attention-deficit/hyperactivity disorder (ADHD) are at greater risk for unemployment. Pharmacological treatment is effective in reducing the core symptoms of ADHD, but whether it helps to reduce the unemployment rate among adult patients remains unclear. To investigate the association between use of ADHD medication and long-term unemployment in working-age adults with ADHD. Data for this population-based cohort study were extracted from Swedish national registers. Among 25 358 individuals with ADHD born from 1958 to 1978, 12 875 middle-aged adults among the workforce were included. The longitudinal cohort was followed up from January 1, 2008, to December 31, 2013. Data were analyzed from March 1, 2020, through May 31, 2021. Use of medication for ADHD during the previous 2 years was the main exposure, as both categorical and continuous variables. Yearly accumulated unemployed days were derived from the Public Employment Service, and long-term unemployment was defined as 90 or more days of unemployment per year. Overall and sex-specific relative risks (RRs) with 95% CIs were estimated using generalized estimating equations. Among 12 875 individuals with ADHD (5343 women [41.50%] and 7532 men [58.50%]; mean [SD] age, 37.9 [5.6] years), the use of ADHD medications during the previous 2 years was associated with a 10% lower risk of long-term unemployment in the following year (adjusted RR, 0.90 [95% CI, 0.87-0.95]). An association between use of ADHD medications and long-term unemployment was found among women (RR, 0.82 [95% CI, 0.76-0.89]) but not men (RR, 0.96 [95% CI, 0.91-1.01]). Longer treatment duration was associated with a lower risk of subsequent long-term unemployment among women (RR for use of 1-6 months, 0.86 [95% CI, 0.78-0.95]; RR for use of 18-24 months, 0.72 [95% CI, 0.58-0.90]; P < .001 for trend). Within-individual comparisons showed that the long-term unemployment rate was lower during periods of ADHD medication treatment compared with nontreatment periods (RR, 0.89; 95% CI, 0.85-0.94). The findings of this cohort study suggest that the use of ADHD medication is associated with a lower risk of subsequent long-term unemployment for middle-aged women. These findings should be considered together with the existing knowledge of risks and benefits of ADHD medication when developing treatment plans for working-age adults.
Identifiants
pubmed: 35476068
pii: 2791570
doi: 10.1001/jamanetworkopen.2022.6815
pmc: PMC9047436
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e226815Références
Scand J Public Health. 2020 Mar;48(2):125-133
pubmed: 31057049
Clin Neuropharmacol. 2012 May-Jun;35(3):125-33
pubmed: 22561876
Evid Based Ment Health. 2021 Nov;24(4):146-152
pubmed: 33795353
Occup Environ Med. 2014 Mar;71(3):183-8
pubmed: 24401871
Psychol Med. 2020 Mar;50(4):529-541
pubmed: 32036811
Clin Psychol Rev. 2015 Aug;40:15-27
pubmed: 26046624
J Clin Psychiatry. 2008 Nov;69(11):1766-75
pubmed: 19026251
PLoS One. 2021 Mar 17;16(3):e0247724
pubmed: 33730071
BMC Psychiatry. 2013 Feb 17;13:59
pubmed: 23414364
BMC Public Health. 2019 Mar 28;19(1):347
pubmed: 30922278
BMC Med. 2012 Sep 04;10:99
pubmed: 22947230
N Engl J Med. 2020 Sep 10;383(11):1050-1056
pubmed: 32905677
J Epidemiol Community Health. 2010 Jan;64(1):22-8
pubmed: 19289388
Neurosci Biobehav Rev. 2021 Sep;128:789-818
pubmed: 33549739
J Clin Psychiatry. 2010 Apr;71(4):381-90
pubmed: 20361900
Soc Sci Med. 2019 Feb;222:305-314
pubmed: 30677644
Lancet. 2020 Feb 8;395(10222):450-462
pubmed: 31982036
Neuropsychiatr Dis Treat. 2018 May 07;14:1149-1161
pubmed: 29765219
BMJ Open. 2018 Mar 2;8(3):e019700
pubmed: 29500213
J Atten Disord. 2012 Oct;16(7):544-52
pubmed: 21725028
Eur J Epidemiol. 2017 Sep;32(9):765-773
pubmed: 28983736
Am J Public Health. 1985 May;75(5):502-6
pubmed: 3985238
Psychol Med. 2012 Jan;42(1):195-204
pubmed: 21733214
Int Rev Neurobiol. 2008;83:1-10
pubmed: 18929073
Eur J Epidemiol. 2019 Apr;34(4):423-437
pubmed: 30929112
Lancet Psychiatry. 2018 Sep;5(9):727-738
pubmed: 30097390
Biol Psychiatry. 2019 Sep 1;86(5):335-343
pubmed: 31155139
J Psychiatr Res. 2020 Apr;123:21-30
pubmed: 32014701
Eur J Epidemiol. 2016 Feb;31(2):125-36
pubmed: 26769609
Child Adolesc Psychiatr Clin N Am. 2000 Jul;9(3):711-26
pubmed: 10944664
Arch Gen Psychiatry. 2012 Dec;69(12):1295-303
pubmed: 23070149
Eur Arch Psychiatry Clin Neurosci. 2007 Oct;257(7):371-7
pubmed: 17902010
Neuropsychiatr Dis Treat. 2014 Aug 22;10:1543-69
pubmed: 25187718
J Atten Disord. 2008 May;11(6):720-7
pubmed: 17968028
Nat Rev Dis Primers. 2015 Aug 06;1:15020
pubmed: 27189265
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Am J Mens Health. 2019 May-Jun;13(3):1557988319857009
pubmed: 31184251
J Atten Disord. 2009 Sep;13(2):175-87
pubmed: 19372500
Eur Arch Psychiatry Clin Neurosci. 2012 Feb;262(1):79-86
pubmed: 21499942
Neuropsychiatr Dis Treat. 2008 Apr;4(2):389-403
pubmed: 18728745
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):554-60
pubmed: 21185347
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791